Recent News for RLAY - Relay Therapeutics, Inc.

Date Title
Feb 4 Relay Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2021 Oncology Day
Jan 22 Relay Therapeutics (RLAY) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow
Jan 21 The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
Jan 14 We Think Relay Therapeutics (NASDAQ:RLAY) Can Easily Afford To Drive Business Growth
Jan 6 SoftBank’s Son Is Poised for Another IPO Windfall in 2021
Jan 6 Relay Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
Dec 17 Is RLAY A Good Stock To Buy Now?
Dec 14 Relay Therapeutics inks deal for RLY-1971 with Genentech
Dec 14 Relay Therapeutics Announces a Worldwide License and Collaboration Agreement with Genentech for RLY-1971
Nov 25 The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback
Nov 18 The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted
Nov 12 Relay Therapeutics reports Q3 results
Nov 12 Relay Therapeutics Reports Third Quarter 2020 Financial Results
Oct 16 Are Insiders Buying Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock?
Oct 3 These Are The Four Biotech Stocks Recently Pitched At The Ira Sohn Conference
Sep 23 Relay Therapeutics rallies 7% on EcoR1 pitch
Sep 21 51 Stocks Moving In Monday's Mid-Day Session
Sep 7 Relay Therapeutics: Heavily Backed Biotech Brains Trust Looks A Long-Term Buy
Sep 4 Dosing underway in Relay Therapeutics' first-in-human RLY-4008 trial
Sep 3 Relay Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Trial of RLY-4008, a Highly Selective FGFR2 Inhibitor
Aug 27 Relay Therapeutics EPS misses by $5.03
Aug 27 Relay Therapeutics Reports Second Quarter 2020 Financial Results
Back to the Main RLAY Page...